Perhaps email them with this suggestion.. honestly, it couldn’t hurt … they aren’t a PE firm they are scientists … research and development of medicine is a far different animal than Twitter pr … they’ve shown they are receptive to constructive feedback as shown this summer with the rs debacle. This company has huge potential with the patent :)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.